Neptune Files for Revocation of Aker's Australian Patents

Neptune Files for Revocation of Aker's Australian Patents

LAVAL, Quebec, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies and
Bioressources Inc. (Nasdaq:NEPT) (TSX:NTB), ("Neptune"), the pioneer in the
krill oil industry, which holds a vast international patent estate covering
krill oil compositions and methods of use, announces that it has filed for the
revocation of all of Aker Biomarine ASA's Australian patents before the
Federal Court.

More specifically, Neptune is seeking a declaration that all the claims in
Aker's patents, namely the standard patent No. 2008231570 and the innovation
patents Nos. 2012101332, 2012101333, 2012101334 and 2012101335 (the "Aker
Patents") are, and at all materials times have been, invalid. The Aker Patents
claim a krill oil composition and methods of extraction that lack novelty and
are not patentable inventions. Neptune marketed its NKO^® krill oil product
many years before Aker filed for these patents in Australia.

"The method and the compositions claimed in the Aker Patents are invalid and
were obtained by false suggestion and misrepresentation, as stated in the
documents filed by Neptune before the Federal Court of Australia," declared
Neptune's Chief Global Strategy Officer, Dr. Tina Sampalis. "Neptune is the
pioneer in the krill oil industry and, as such, we must protect our clients
and our pharmaceutical subsidiaries, and ensure that invalid patents are not
used to threaten Neptune's business partners. We are confident that the
Federal Court of Australia will find that the Aker Patents are invalid."

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and
commercialization of marine-derived omega-3 polyunsaturated fatty acids, or
PUFAs. Neptune has a patented process of extracting oils from Antarctic krill,
which omega-3 PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label primarily in the
U.S., European and Asian neutraceutical markets. Neptune's lead products,
Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule
form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti (TSX-V:APO) and NeuroBioPharm, in which
Neptune respectively holds 57% and 99% of the voting rights, Neptune is also
pursuing opportunities in the medical food and prescription drug markets.
Acasti and NeuroBioPharm respectively focus on the research and development of
safe and therapeutically effective compounds for highly prevalent
atherosclerotic conditions, such as cardiometabolic disorders and
cardiovascular diseases, and for neurodegenerative and inflammation related
conditions. Acasti's lead prescription drug candidate is CaPre®, a purified
high omega-3 phospholipid concentrate derived from Neptune krill oil being
developed to address the prevention and treatment of cardiometabolic
disorders, including hypertriglyceridemia, which is characterized by
abnormally high levels of triglycerides.

Forward Looking Statements

Certain statements included in this press release may be considered
forward-looking information within the meaning of Canadian securities laws and
forward-looking statements within the meaning of U.S. federal securities laws,
both of which we refer to as forward-looking statements. Such statements
involve known and unknown risks, uncertainties and other factors that may
cause results, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking
statements are based on Neptune's current beliefs as well as assumptions made
by and information currently available to Neptune and relate to, among other
things, Neptune's strategy, strategic goals, research and development
activities, research and clinical testing outcome, future operations, future
financial position, future revenues/results, projected costs, prospects and
plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties identified by
Neptune in its amended and restated annual information form dated September
11, 2012, in its press release announcing an action plan to resume operations
and supply customers dated November 26, 2012 and in its other public
securities filings available at www.sedar.com and www.sec.gov/edgar.shtml,
actual events may differ materially from current expectations. Except as
required by law, Neptune disclaims any intention or obligation to update or
revise any forward-looking statements.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com
        
         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com
 
Press spacebar to pause and continue. Press esc to stop.